Back to top
more

Denali Therapeutics (DNLI)

(Delayed Data from NSDQ)

$14.29 USD

14.29
2,013,687

-0.15 (-1.04%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $14.28 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -1.20% and 64.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Add Intra-Cellular Therapeutics (ITCI) Stock Now

by Zacks Equity Research

Intra-Cellular's (ITCI) product revenues are primarily driven by higher sales of its schizophrenia and bipolar disorder drug Caplyta. Caplyta is also being evaluated for other CNS indications.

Zacks Equity Research

Denali Therapeutics Inc. (DNLI) Moves 17.7% Higher: Will This Strength Last?

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Why Is Denali Therapeutics Inc. (DNLI) Down 27.4% Since Last Earnings Report?

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Denali (DNLI) Q2 Earnings Beat, Pipeline Progress in Focus

by Zacks Equity Research

Denali (DNLI) incurs narrower-than-expected Q2 loss while collaboration revenues beat estimates.

Zacks Equity Research

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 7.69% and 15.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Denali Therapeutics Inc. (DNLI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Biogen (BIIB) Inks Deal for Alectos' Parkinson's Disease Drug

by Zacks Equity Research

Biogen (BIIB) signs a deal with privately-held Alectos Therapeutics to gain an exclusive global license to the latter's pre-clinical oral selective GBA2 inhibitor, AL01811, targeting Parkinson's disease.

Zacks Equity Research

Biogen (BIIB), Denali Begin Mid-Stage Study on Parkinson's Drug

by Zacks Equity Research

Biogen (BIIB) and partner Denali initiate a mid-stage study to evaluate their oral LRRK2 inhibitor, BIIB122, in adults with early-stage Parkinson's disease. A late-stage study is planned to start later in 2022.

Zacks Equity Research

Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -12.77% and 72.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

AVEO (AVEO) delivered earnings and revenue surprises of -15.38% and 1.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Denali Therapeutics Inc. (DNLI) Up 7.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Denali Therapeutics Inc. (DNLI) Moves 7.5% Higher: Will This Strength Last?

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Denali (DNLI) Begins Frontotemporal Dementia-Granulin Study

by Zacks Equity Research

Denali (DNLI) starts an early-stage study of DNL593 for treating frontotemporal dementia (FTD) due to mutations in the granulin gene (GRN) in collaboration with Takeda.

Zacks Equity Research

Denali (DNLI) Q4 Loss Wider Than Expected, Revenues Lag

by Zacks Equity Research

Denali (DNLI) announces wider-than-expected loss per share for fourth-quarter 2021. Revenues also miss estimates.

Zacks Equity Research

Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -51.22% and 67.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Denali Therapeutics Inc. (DNLI) Q4 Earnings Expected to Decline

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Denali (DNLI) Stock Up Despite Wider-Than-Expected Q3 Loss

by Zacks Equity Research

Denali (DNLI) announces wider-than-expected loss per share for third-quarter 2021. Nonetheless, its shares rise following the announcement.

Zacks Equity Research

Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -35.29% and -78.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

New Strong Sell Stocks for October 12th

by Zacks Equity Research

ONEM, DNLI, FMC, GPL, and LGO have been added to the Zacks Rank #5 (Strong Sell) List on October 12, 2021.

Zacks Equity Research

Denali Therapeutics Inc. (DNLI) Up 5.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Biogen (BIIB) Stock Up This Year So Far on Aduhelm Approval

by Zacks Equity Research

Biogen's (BIIB) new Alzheimer's drug, Aduhelm should bring in huge revenues, if successfully commercialized.